Autoimmunity in Thrombotic Thrombocytopenic Purpura

ABSTRACT

In the last few years, an autoimmune hypothesis for the pathogenesis of thrombotic thrombocytopenic purpura (TTP) has been proposed often, with variable success because of inconsistent supporting data. We are now aware that at least one subgroup of TTP patients does present with pathogenic autoantibodies (i.e, anti-ADAMTS13); this group consequently is a putative candidate for a curative treatment including plasma exchange (still the cornerstone of TTP treatment), together with corticosteroids or other immunosuppressants. Furthermore, for patients not responding to or relapsing following plasma exchange, the use of stronger immunosuppression (e.g., with the use of the anti-CD20 monoclonal antibody rituximab) should be considered as appropriate. Conversely, few data are actually available regarding the complex relationship between TTP and the antiphospholipid (aPL) syndrome, as well as other autoimmune diseases. Indeed, a correct differential diagnosis should be done on the basis of both different clinical presentations and autoantibody profile. At present, the presence of aPL antibodies should give evidence against a diagnosis of TTP, even though we cannot exclude that aPL antibodies may, in a minority of patients, be associated with a primary endothelial damage ultimately resulting in overt TTP.

KEYWORDS

Thrombotic thrombocytopenic purpura (TTP) - ADAMTS13 antibodies - antiphospholipid syndrome - immunosuppressants - rituximab.

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc NY Pathol Soc. 1924;  24 21-24
• 2 Singer K, Bornstein F P, Wile S A. Thrombotic thrombocytopenic purpura. Hemorrhagic diathesis with generalized platelet thromboses.  Blood. 1947;  2 542-544
• 3 Neame P B. Immunologic and other factors in thrombotic thrombocytopenic purpura (TTP).  Semin Thromb Hemost. 1980;  6 416-429
• 4 Rock G A, Shumak K H, Buskard N A et al.. Comparison of plasma-exchange with plasma-infusion in the treatment of thrombotic thrombocytopenic purpura.  N Engl J Med. 1991;  325 393-397
• 5 Moses J, Lichtman S M, Brody J, Wisch N, Moake J L. Hairy cell leukemia in association with thrombotic thrombocytopenic purpura and factor VIII antibodies.  Leuk Lymphoma. 1996;  22 351-354
• 6 Tada T, Kishimoto H. An autopsy case of thrombotic thrombocytopenic purpura (TTP) complicated with systemic lupus erythematosus (SLE)-demonstration of anti-platelet antibody.  Rinsho Ketsueki. 1980;  21 1773-1780
• 7 Bodensteiner D, Rosenfeld C. Elevated platelet-surface-bound IgM in thrombotic thrombocytopenic purpura.  South Med J. 1988;  81 81-83
• 8 Nakajima T, Koyama T, Kakishita E, Nagai K. Inhibitory effects of TTP sera on binding of anti-platelet glycoprotein IIb-IIIa monoclonal antibodies to human vascular endothelial cells.  Am J Hematol. 1987;  25 115-118
• 9 Stein R S, Flexner J M. Persistently perplexing purpuras: thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura.  Ann Intern Med. 1994;  121 720-721 (letter)
• 10 Leung D Y, Moake J L, Havens P L, Kim M, Pober J S. Lytic anti-endothelial cell antibodies in haemolytic-uraemic syndrome.  Lancet. 1988;  23 183-186
• 11 Koenig D W, Barley-Maloney L, Daniel T O. A Western blot assay detects autoantibodies to cryptic endothelial antigens in thrombotic microangiopathies.  J Clin Immunol. 1993;  13 204-211
• 12 Tandon N N, Rock G, Jamieson G A. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura.  Br J Haematol. 1994;  88 816-825
• 13 Porta C, Caporali R, Montecucco C. Thrombotic thrombocytopenic purpura and autoimmunity: a tale of shadows and suspects.  Haematologica. 1999;  84 260-269
• 14 Gorini M, Luliri P. Steroids: what role in TTP?.  Transfus Sci. 1992;  13 73-76
• 15 Bobbio-Pallavicini E, Porta C, Centurioni R et al.. Vincristine sulfate for the treatment of thrombotic thrombocytopenic purpura refractory to plasma-exchange.  Eur J Haematol. 1994;  52 222-226
• 16 Moake J L, Rudy C K, Troll J H et al.. Therapy of chronic relapsing thrombotic thrombocytopenic purpura with prednisone and azathioprine.  Am J Hematol. 1985;  20 73-79
• 17 Fessler B J. Thrombotic syndromes and autoimmune diseases.  Rheum Dis Clin North Am. 1997;  23 461-479
• 18 Sadler J E. Biochemistry and genetics of von Willebrand factor.  Annu Rev Biochem. 1998;  67 395-424
• 19 Dent J A, Berkowitz S D, Ware J, Kasper C K, Ruggeri Z M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.  Proc Natl Acad Sci USA. 1990;  87 6306-6310
• 20 Moake J L, Rudy C K, Troll J H et al.. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 21 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98 1662-1666
• 22 Gerritsen H E, Robles R, Lämmle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease.  Blood. 2001;  98 1654-1661
• 23 Zheng X, Chung D, Takayama T K, Majerus E M, Sadler J E, Fujikawa K. Structure of von Willebrand factor-cleaving protease (ADAMTS-13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276 41059-41063
• 24 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.  Nature. 2001;  413 488-494
• 25 Soejima K, Mimura N, Hirashima M et al.. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease?.  J Biochem (Tokyo). 2001;  130 475-480
• 26 Plaimauer B, Zimmermann K, Volkel D et al.. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS-13).  Blood. 2002;  100 3626-3632
• 27 Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lämmle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 28 Furlan M, Lämmle B. Deficiency of von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura.  Baillieres Clin Haematol. 1998;  11 509-514
• 29 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 30 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 31 Furlan M, Robles R, Solenthaler M, Lämmle B. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura.  Blood. 1998;  91 2839-2846
• 32 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS-13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci U S A. 2002;  99 11902-11907
• 33 Schneppenheim R, Budde U, Oyen F et al.. Von Willebrand factor cleaving protease and ADAMTS-13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
• 34 Antoine G, Zimmermann K, Plaimauer B et al.. ADAMTS-13 gene defects in two brothers with thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS-13.  Br J Haematol. 2003;  120 821-824
• 35 Savasan S, Lee S K, Ginsburg D, Tsai H M. ADAMTS-13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal vWF cleaving protease activity.  Blood. 2003;  101 4449-4451
• 36 Assink K, Schiprost R, Allford S et al.. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.  Kidney Int. 2003;  63 1995-1999
• 37 Matsumoto M, Kokame K, Soejima K et al.. Molecular characterization of ADAMTS-13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2004;  103 1305-1310
• 38 Veyradier A, Lavergne J M, Ribba A S et al.. The candidate ADAMTS-13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).  J Thromb Haemost. 2004;  2 424-429
• 39 Furlan M, Lämmle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome: the role of von Willebrand factor-cleaving protease.  Best Pract Res Clin Haematol. 2001;  14 437-454
• 40 Kremer-Hovinga J A, Studt J D, Lämmle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP).  Pathophysiol Haemost Thromb. 2004;  33 417-421
• 41 Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab.  Ann Oncol. 2003;  14 520-535
• 42 Levine T D, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituximab.  Neurology. 1999;  52 1701-1704
• 43 Berentsen S, Tjonnfjord G E, Brudevold R et al.. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease.  Br J Haematol. 2001;  115 79-83
• 44 Specks U, Fervenza F C, McDonald T J, Hogan M CE. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.  Arthritis Rheum. 2001;  44 2836-2840
• 45 Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.  Blood. 2001;  98 952-957
• 46 Dimopoulos M A, Zervas C, Zomas A et al.. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.  Clin Lymphoma. 2002;  3 163-166
• 47 Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy.  Eur J Haematol. 2002;  68 243-246
• 48 Motto D G, Williams J A, Boxer L A. Rituximab for refractory childhood autoimmune hemolytic anemia.  Isr Med Assoc J. 2002;  4 1006-1008
• 49 Perrotta S, Locatelli F, LaManna A, Cennamo L, DeStefano P, Nobili B. Anti-CD20 monoclonal antibody (rituximab) for life-threatening autoimmune haemolytic in a patient with systemic lupus erythematosus.  Br J Haematol. 2002;  116 465-467
• 50 Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P. Rituximab for idiopathic membranous nephropathy.  Lancet. 2002;  360 923-924
• 51 Salopek T G, Logsetty S, Tredget E E. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.  J Am Acad Dermatol. 2002;  47 785-788
• 52 Zaja F, De Vita S, Mazzaro C et al.. Efficacy and safety of rituximab in type II mixed cryoglobulinemia.  Blood. 2003;  101 3827-3834
• 53 Zaja F, Iacona I, Masolini P et al.. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.  Haematologica. 2002;  87 189-195
• 54 Renaud S, Gregor M, Fuhr P et al.. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies.  Muscle Nerve. 2003;  27 611-615
• 55 Trape G, Fianchi L, Lai M et al.. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders.  Haematologica. 2003;  88 223-225
• 56 Zecca M, Nobili B, Ramenghi U et al.. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.  Blood. 2003;  101 3857-3861
• 57 Gutterman L A, Kloster B, Tsai H M. Rituximab therapy for refractory thrombotic thrombocytopenic purpura.  Blood Cells Mol Dis. 2002;  28 385-391
• 58 Chemnitz J, Draube A, Scheid C et al.. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab.  Am J Hematol. 2002;  71 105-108
• 59 Zheng X, Pallera A M, Goodnough L T, Sadler J E, Blinder M A. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.  Ann Intern Med. 2003;  138 105-108
• 60 Tsai H M, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura.  Eur J Haematol. 2003;  70 183-185
• 61 Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai H M. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature.  Br J Haematol. 2004;  124 787-795
• 62 Sallah S, Husain A, Wan J Y, Nguyen N P. Rituximab in patients with refractory thrombotic thrombocytopenic purpura.  J Thromb Haemost. 2004;  2 834-836
• 63 Stein G Y, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide.  Int J Hematol. 2004;  80 94-96
• 64 Ahmad A, Aggarwal A, Sharma D et al.. Rituximab for treatment of refractory thrombotic thrombocytopenic purpura (TTP).  Am J Hematol. 2004;  77 171-176
• 65 Reddy P S, Deauna-Limayo D, Cook J D et al.. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura.  Ann Hematol. 2005;  84 232-235
• 66 Ruiz J, Koduri P R, Valdivieso M, Shah P C. Refractory post-pancreatitis thrombotic thrombocytopenic purpura: response to rituximab.  Ann Hematol. 2005;  84 267-268
• 67 Koulova L, Alexandrescu D, Dutcher J P, O'Boyle K P, Eapen S, Wiernik P H. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.  Am J Hematol. 2005;  78 49-54
• 68 Galbusera M, Bresin E, Noris M et al.. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report.  Blood. 2005;  106 925-928
• 69 Fakhouri F, Vernant J P, Veyradier A et al.. Efficiency of curative and prophylactic treatment with Rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases.  Blood. 2005;  106 1932-1937
• 70 Montecucco C, Caporali R. Hemocytopenias in antiphospholipid syndrome. In: Hughes GRV, Khamashta M Hughes Syndrome. London; Springler-Verlag 2000: 20-31
• 71 Durand J M, Lefevre P, Kaplanski G, Soubeyrand J. Thrombotic microangiopathy and the antiphospholipid antibody syndrome.  J Rheumatol. 1991;  18 1916-1918
• 72 Musio F, Bohen E M, Yuan C M et al.. Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus.  Semin Arthritis Rheum. 1998;  28 1-19
• 73 Huang J J, Chen M W, Sung J M et al.. Postpartum hemolytic uremic syndrome associated with antiphospholipid antibody.  Nephrol Dial Transplant. 1998;  13 182-186
• 74 Falcini F, Taccetti G, Ermini M et al.. Catastrophic antiphospholipid antibody syndrome in pediatric systemic lupus erythematosus.  J Rheumatol. 1997;  24 389-392
• 75 Vasoo S, Thumboo J, Fong K Y. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: disease activity and the use of cytotoxic drugs.  Lupus. 2002;  11 443-450
• 76 Devinsky O, Petito C K, Alonso D R. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli, and thrombotic thrombocytopenic purpura.  Ann Neurol. 1988;  23 380-384
• 77 Porta C, Bobbio-Pallavicini E, Centurioni R et al.. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus.  J Rheumatol. 1993;  20 1625-1626
• 78 Caramaschi P, Riccetti M M, Pasini A F et al.. Systemic lupus erythematosus and thrombotic thrombocytopenic purpura. Report of three cases and review of the literature.  Lupus. 1998;  7 37-41
• 79 Jorfen M, Callejas J L, Formiga F et al.. Fulminant thrombotic thrombocytopenic purpura in systemic lupus erythematosus.  Scand J Rheumatol. 1998;  27 76-77
• 80 Montecucco C, Longhi M, Caporali R et al.. Hematological abnormalities associated with anticardiolipin antibodies.  Haematologica. 1989;  74 195-204
• 81 Espinosa G, Bucciarelli S, Cervera R et al.. Thrombotic microangiopathic haemolytic anemia and antiphospholipid antibodies.  Ann Rheum Dis. 2004;  63 730-736
• 82 Ardiles L G, Olavarria F, Elgueta M et al.. Anticardiolipin antibodies in classic pediatric hemolytic-uremic syndrome: a possible pathogenic role.  Nephron. 1998;  78 278-283
• 83 Trent K, Neustater B R, Lottenberg R. Chronic thrombotic thrombocytopenic purpura and antiphospholipid antibodies: A report of two cases.  Am J Hematol. 1997;  54 155-159
• 84 Knovich M A, Craver K, Matulis M D et al.. Simplified assay for VWF cleaving protease (ADAMTS-13) activity and inhibitor in plasma.  Am J Hematol. 2004;  76 286-290
• 85 Mannucci P M, Vanoli M, Forza I, Canciani M T, Scorza R. Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue disease (systemic lupus erythematosus and systemic sclerosis).  Haematologica. 2003;  88 914-918
• 86 Rick M E, Austin H, Leitman S F, Krizek D M, Aronson D L. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS-13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.  Am J Hematol. 2004;  75 96-100
• 87 Bettendorf U, Potters R. Moschcowitz's syndrome following D-penicillamine medication.  Med Welt. 1975;  26 291-295
• 88 Speth P A, Boerboons A M, Holdrinet R S, Van de Putte L B, Meyer J W. Thrombotic thrombocytopenic purpura associated with D-penicillamine treatment in rheumatoid arthritis.  J Rheumatol. 1982;  9 812-813
• 89 Trice J M, Pinals R S, Plitman G I. Thrombotic thrombocytopenic purpura during penicillamine therapy in rheumatoid arthritis.  Arch Intern Med. 1983;  143 1487-1488
• 90 Ahmed F, Sumalnop V, Spain D M, Tobin M S. Thrombotic thrombocytopenic purpura during penicillamine therapy.  Arch Intern Med. 1978;  138 1292-1293
• 91 Harrison E E, Hickman J W. Hemolytic anemia and thrombocytopenia associated with D-penicillamine therapy.  South Med J. 1975;  68 113-115
• 92 Bobbio-Pallavicini E, Porta C, Fornasari P M, Viarengo G L, Ascari E. Thrombotic thrombocytopenic purpura (TTP): retrospective study on 84 patients and therapeutical prospects.  Transfus Sci. 1992;  13 39-44